SCHEMBL5778799

SCHEMBL5778799

C[C@H](CC(=O)O)c1ccc2c(c1)CCCN2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.54
KDM4E B2RXH2 2/20 0.54
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
GAA P10253 3/20 0.44
ALDH1A1 P00352 3/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
THRB P10828 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
CASP7 P55210 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
TSHR P16473 1/20 0.41
FFAR1 O14842 2/20 0.40
ITGB3 P05106 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5778803 1.00 MAPT (0.54) MAPTKDM4ECA12CA1CA2
SCHEMBL5779828 0.92 ALDH1A1 (0.47) MAPTKDM4ECA12CA1CA2
SCHEMBL5779829 0.92 ALDH1A1 (0.47) MAPTKDM4ECA12CA1CA2
SCHEMBL6140914 0.82 MAPT (0.57) MAPTKDM4ECA12CA1CA2
SCHEMBL13588584 0.81 GAA (0.52) MAPTKDM4ECA12CA1CA2
SCHEMBL11334467 0.79 KDM4E (0.62) MAPTKDM4ECA12CA1CA2
SCHEMBL6421470 0.78 MAPT (0.50) MAPTKDM4ECA12CA1CA2
SCHEMBL7420967 0.76 MAPT (0.52) MAPTKDM4ECA12CA1CA2
SCHEMBL5780658 0.76 GAA (0.48) MAPTKDM4ECA12CA1CA2
SCHEMBL5782404 0.76 ALDH1A1 (0.48) MAPTKDM4EGAAALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1114028-B1 AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION AVENTIS PHARMA LTD (GB) 2006-11-29 EP disclosed
US-6608084-B1 Treatment of human or non-human animal patient suffering from, or subject to, condition which can be ameliorated by administration of inhibitor of alpha 4 beta 1 mediated cell adhesion AVENTIS PHARMA LTD. (GB) 2003-08-19 US disclosed
EP-1114028-A1 AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION Aventis Pharma Limited (GB) 2001-07-11 EP disclosed
WO-2000015612-A1 AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION AVENTIS PHARMA LIMITED (GB) 2000-03-23 WO disclosed